Join us live on Wednesday, March 24, 2021, from 3:00 PM ET to 4:00 PM ET

Speakers:

• Jennifer Lai, MD, MBA • Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
• Mara McAdams DeMarco, PhD • Associate Professor, Johns Hopkins University, Baltimore, MD
• Evan Kransdorf, MD, PhD • Assistant Director, Heart Transplant Research and Education, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Moderator:

• Lianne Singer, MD, FRCPC • Professor of Medicine, University Health Network, University of Toronto, Toronto, ON

Join us live on Monday, November 2, 2020, from 4:00 PM ET to 5:00 PM ET • Hosted by the AST Live Donor Community of Practice

"Evaluating multiple living kidney donor candidates simultaneously is more cost-effective than sequentially."
(Kidney International. doi.org/10.1016/j.kint.2020.06.015)

In this article:
When multiple living donor candidates come forward to donate a kidney to the same recipient, some living donor programs evaluate one candidate at a time to avoid unnecessary evaluations. Evaluating multiple candidates concurrently rather than sequentially may be cost-effective from a societal perspective if it reduces the time recipients spend on dialysis. [The authors] used a simple decision tree to estimate the cost-effectiveness of evaluating two to four candidates simultaneously rather than sequentially as potential kidney donors for the same intended recipient...[and found that] living donor programs should consider evaluating up to four living donor candidates simultaneously when they come forward for the same recipient as health care system costs incurred are more than offset by avoided dialysis costs.

Speakers:
Steven Habbous, PhD • Western University, London, ON
Amit Garg, MD, PhD • Western University, London, ON

Moderator:
Krista Lentine, MD, PhD • Saint Louis University Transplant Center, Saint Louis, MO
Neekita Garg, MD • University of Wisconsin-Madison, Madison, WI

AST/AJT Journal Clubs are free for both members and non-members. Pre-registration is required.

Tuesday, August 25, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates."
(Am J Transplant. 2020 May 06. doi.org/10.1111/ajt.15976.)

In this article:
The most significant risk for developing Cytomegalovirus (CMV) infection after transplant depends upon donor (D) and recipient (R) CMV serostatus. In 2012, [an] Organ Procurement Organization (OPO) began a novel pretransplant CMV prevention strategy via matching deceased kidney donors and recipients by CMV serostatus... After the matching protocol, high‐risk D+R− were reduced from 18.5% to 2.9%, whereas low‐risk D−R− were increased from 13.5% to 24%. There was no adverse effect on transplant rates and no differential effect on waiting times for R+ vs R− after the protocol was implemented. [The authors believe this] protocol could be implemented on a regional or national level to optimize low and high‐risk CMV seroprofiles and potentially improve CMV‐related outcomes in kidney transplantation.

Speaker:
Joe Lockridge, MD • Portland VA Health Care System, Oregon Health and Science University, Portland, OR

Moderators:
Jennifer Chow, MD, MS • Tufts Medical Center, Boston, MA
Jonathan Maltzman, MD, PhD, FAST • Stanford University, Palo Alto, CA

AST/AJT Journal Clubs are free for both members and non-members. Pre-registration is required.

Speakers:
Norah Terrault, MD, MPH • Professor of Medicine, Keck School of Medicine of USC, Los Angeles, CA
Deirdre Sawinski, MD • Associate Professor of Medicine, University of Pennsylvania, Philadelphia, PA

Moderator:
Christine Durand, MD • Associate Professor of Medicine, Johns Hopkins University, Baltimore, MD

After participating in this webinar, the attendee will be able to:

1. Understand the evolution of and current state of knowledge using HCV donors (NAT+/-) for liver transplantation
2. Understand the evolution of and current state of knowledge using HCV donors (NAT+/-) for kidney transplantation
3. Describe future directions for utilization of HCV donors (NAT+/-) for abdominal organ transplantation

AST would like to thank the Infectious Disease (IDCOP), Kidney Pancreas (KPCOP), and Liver and Intestinal (LICOP) Communities of Practice for each recommending "HCV" as a topic for the 2019-2020 T3 series. The concept was expanded into two HCV NAT+/- sessions, one covering "HCV NAT+/- in Abdominal Organ Transplantation" and another covering "HCV NAT+/- in Thoracic Organ Transplantation." 

Scheduled for Monday, May 4th, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted by the Kidney Pancreas Community of Practice (KPCOP)

"The survival advantage of pancreas after kidney transplant."
(Am J Transplant. 2019 Mar;19(3):823-830. doi: 10.1111/ajt.15106. Epub 2018 Oct 4.)

In this article:
"Patient survival after pancreas after kidney transplant (PAK) has been reported to be inferior to patient survival after simultaneous pancreas-kidney transplant (SPK). The authors examine national data to further explore allograft (kidney and pancreas) and patient survival after PAK... [The authors found that] successful PAK offers a survival advantage compared with receiving neither a kidney nor a pancreas transplant. These data also suggest that receiving a pancreas (after kidney) transplant may have a protective effect on the kidney allograft."

Speaker:
Jonathan Fridell, MD • Indiana University School of Medicine, Indianapolis, IN

Moderator:
Jon Odorico, MD • University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI

Live webinars in the AST/AJT Journal Club series are open to both members and non-members. Pre-registration is required.